Loading...
Header Logo
Keywords
Last Name
Institution

CASSIAN YEE

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kim TJ, Park G, Kim J, Lim SA, Kim J, Im K, Shin MH, Fu YX, Del Rio ML, Rodriguez-Barbosa JI, Yee C, Suh KS, Kim SJ, Ha SJ, Lee KM. CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun. 2019 Jul 22; 10(1):3258. PMID: 31332204.
      View in: PubMed
    2. Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM. Systemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019 Aug; 7(8):1237-1243. PMID: 31171504.
      View in: PubMed
    3. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5). PMID: 31096717.
      View in: PubMed
    4. Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia. 2019 Apr 25. PMID: 31028278.
      View in: PubMed
    5. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107. PMID: 30995944.
      View in: PubMed
    6. Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019; 10:496. PMID: 31024520.
      View in: PubMed
    7. Choi HY, Yang GM, Dayem AA, Saha SK, Kim K, Yoo Y, Hong K, Kim JH, Yee C, Lee KM, Cho SG. Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3ß activities. Breast Cancer Res. 2019 01 16; 21(1):6. PMID: 30651129.
      View in: PubMed
    8. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697. PMID: 30635425.
      View in: PubMed
    9. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 Jan 06; 7(1):2. PMID: 30612580.
      View in: PubMed
    10. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 Oct 11; 6(1):103. PMID: 30305177.
      View in: PubMed
    11. Song KH, Kim JH, Lee YH, Bae HC, Lee HJ, Woo SR, Oh SJ, Lee KM, Yee C, Kim BW, Cho H, Chung EJ, Chung JY, Hewitt SM, Chung TW, Ha KT, Bae YK, Mao CP, Yang A, Wu TC, Kim TW. Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. J Clin Invest. 2018 Aug 31; 128(9):4098-4114. PMID: 30124467.
      View in: PubMed
    12. Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, Chen A, Bao Y, Zhou C, Li S, Yee C, Li Y. ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression. Immunology. 2018 10; 155(2):238-250. PMID: 29791021.
      View in: PubMed
    13. Fan J, Liang H, Shen T, Wang S, Ji X, Yee C, Lu F, Shao Y. Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cell Immunol. 2018 09; 331:30-37. PMID: 29773224.
      View in: PubMed
    14. Yee C. Adoptive T cell therapy: points to consider. Curr Opin Immunol. 2018 04; 51:197-203. PMID: 29730057.
      View in: PubMed
    15. Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri R. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018 Apr 19; 3(8). PMID: 29669940.
      View in: PubMed
    16. Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018 Mar 13; 9(19):14764-14790. PMID: 29599906.
      View in: PubMed
    17. Oh SJ, Cho H, Kim S, Noh KH, Song KH, Lee HJ, Woo SR, Kim S, Choi CH, Chung JY, Hewitt SM, Kim JH, Baek S, Lee KM, Yee C, Park HC, Kim TW. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis. Cancer Res. 2018 05 15; 78(10):2638-2653. PMID: 29437706.
      View in: PubMed
    18. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283. PMID: 29387478.
      View in: PubMed
    19. Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR, Hong SO, Noh KH, Cho H, Chung EJ, Kim JH, Chung JY, Hewitt SM, Baek S, Lee KM, Yee C, Son M, Mao CP, Wu TC, Kim TW. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. Cancer Res. 2017 09 15; 77(18):5039-5053. PMID: 28716899.
      View in: PubMed
    20. Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res. 2017 08; 5(8):618-629. PMID: 28630054.
      View in: PubMed
    21. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11. PMID: 28630682.
      View in: PubMed
    22. Yee C, Lizee GA. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J. 2017 Mar/Apr; 23(2):144-148. PMID: 28410303.
      View in: PubMed
    23. Yee C. From the Guest Editor. Cancer J. 2017 Mar/Apr; 23(2):95-96. PMID: 28410295.
      View in: PubMed
    24. Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo. Sci Immunol. 2017 Feb; 2(8). PMID: 28367538.
      View in: PubMed
    25. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. PMID: 27846884.
      View in: PubMed
    26. Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol. 2016 11 01; 34(31):3787-3795. PMID: 27269940.
      View in: PubMed
    27. Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med. 2016 06 27; 213(7):1133-9. PMID: 27242164.
      View in: PubMed
    28. Ju B, Li D, Ji X, Liu J, Peng H, Wang S, Liu Y, Hao Y, Yee C, Liang H, Shao Y. Interleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice. Cell Immunol. 2016 05; 303:55-65. PMID: 27062692.
      View in: PubMed
    29. Yee C, Lizee G, Schueneman AJ. Endogenous T-Cell Therapy: Clinical Experience. Cancer J. 2015 Nov-Dec; 21(6):492-500. PMID: 26588682.
      View in: PubMed
    30. Kim TJ, Kim M, Kim HM, Lim SA, Kim EO, Kim K, Song KH, Kim J, Kumar V, Yee C, Doh J, Lee KM. Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells. Sci Rep. 2014 Dec 05; 4:7157. PMID: 25475707.
      View in: PubMed
    31. Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014; 2(1):36. PMID: 25317334.
      View in: PubMed
    32. Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One. 2014; 9(5):e96565. PMID: 24794217.
      View in: PubMed
    33. Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014 Jul 01; 74(13):3556-66. PMID: 24769442.
      View in: PubMed
    34. Lee JE, Lim SA, Kim TJ, Kim K, Ng J, Kim YH, Jang IJ, Oh SB, Lee JC, Yee C, Kumar V, Lee KM. NKG2D ligation relieves 2B4-mediated NK-cell self-tolerance in mice. Eur J Immunol. 2014 Jun; 44(6):1802-13. PMID: 24610736.
      View in: PubMed
    35. Hwang SW, Park G, Edwards C, Corbin EA, Kang SK, Cheng H, Song JK, Kim JH, Yu S, Ng J, Lee JE, Kim J, Yee C, Bhaduri B, Su Y, Omennetto FG, Huang Y, Bashir R, Goddard L, Popescu G, Lee KM, Rogers JA. Dissolution chemistry and biocompatibility of single-crystalline silicon nanomembranes and associated materials for transient electronics. ACS Nano. 2014 Jun 24; 8(6):5843-51. PMID: 24684516.
      View in: PubMed
    36. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014 Jan 10; 15(1):927-43. PMID: 24434638.
      View in: PubMed
    37. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014 Jan; 2(1):27-36. PMID: 24432305.
      View in: PubMed
    38. Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev. 2014 Jan; 257(1):250-63. PMID: 24329802.
      View in: PubMed
    39. Park G, Chung HJ, Kim K, Lim SA, Kim J, Kim YS, Liu Y, Yeo WH, Kim RH, Kim SS, Kim JS, Jung YH, Kim TI, Yee C, Rogers JA, Lee KM. Immunologic and tissue biocompatibility of flexible/stretchable electronics and optoelectronics. Adv Healthc Mater. 2014 Apr; 3(4):515-25. PMID: 23996980.
      View in: PubMed
    40. Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res. 2013 Sep 01; 19(17):4550-2. PMID: 23922301.
      View in: PubMed
    41. Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol. 2013 Aug 15; 191(4):1567-77. PMID: 23851683.
      View in: PubMed
    42. Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res. 2013 Apr 15; 73(8):2598-607. PMID: 23580577.
      View in: PubMed
    43. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013 Feb 27; 5(174):174ra27. PMID: 23447018.
      View in: PubMed
    44. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett. 2012 Aug 08; 12(8):4018-24. PMID: 22784189.
      View in: PubMed
    45. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4592-7. PMID: 22393002.
      View in: PubMed
    46. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165. PMID: 22384167.
      View in: PubMed
    47. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15; 118(18):4564-70. PMID: 22359263.
      View in: PubMed
    48. Lee SM, Yee C. Another LAP in the race. Cancer Discov. 2012 Feb; 2(2):107-9. PMID: 22585852.
      View in: PubMed
    49. Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 2012 Feb-Mar; 35(2):131-41. PMID: 22306901.
      View in: PubMed
    50. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson C, Nepom G, Yee C, Cerosaletti K. Ultra-sensitive detection of rare T cell clones. J Immunol Methods. 2012 Jan 31; 375(1-2):14-9. PMID: 21945395.
      View in: PubMed
    51. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem P. Merkel cell polyomavirus-specific CD8? and CD4? T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res. 2011 Nov 01; 17(21):6671-80. PMID: 21908576.
      View in: PubMed
    52. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011 Aug; 18(8):827-34. PMID: 21390072.
      View in: PubMed
    53. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1664-73. PMID: 21325070.
      View in: PubMed
    54. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma. 2011; 2011:438940. PMID: 21331153.
      View in: PubMed
    55. Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh V. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol. 2010 Nov 15; 185(10):5732-42. PMID: 20926796.
      View in: PubMed
    56. Yee C. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 2010 Jul-Aug; 16(4):367-73. PMID: 20693849.
      View in: PubMed
    57. Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol. 2010 Jun 01; 184(11):6514-21. PMID: 20483791.
      View in: PubMed
    58. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009; 4(3):e4749. PMID: 19270751.
      View in: PubMed
    59. Shah KV, Chien AJ, Yee C, Moon RT. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol. 2008 Dec; 128(12):2870-9. PMID: 18563180.
      View in: PubMed
    60. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008 Jun 19; 358(25):2698-703. PMID: 18565862.
      View in: PubMed
    61. Gunn J, Wallen H, Veiseh O, Sun C, Fang C, Cao J, Yee C, Zhang M. A multimodal targeting nanoparticle for selectively labeling T cells. Small. 2008 Jun; 4(6):712-5. PMID: 18528851.
      View in: PubMed
    62. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, Yee C, Wainstok R, Mordoh J. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med. 2008 Jan 25; 6:6. PMID: 18221542.
      View in: PubMed
    63. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2008 Jan 01; 111(1):229-35. PMID: 17921346.
      View in: PubMed
    64. von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, Li Y, Wainstok R, Mordoh J. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med. 2007 Apr 20; 5:19. PMID: 17448240.
      View in: PubMed
    65. Yee C. Adoptive T-cell therapy of cancer. Hematol Oncol Clin North Am. 2006 Jun; 20(3):711-33. PMID: 16762731.
      View in: PubMed
    66. Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50. PMID: 16374636.
      View in: PubMed
    67. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005 Aug 15; 175(4):2261-9. PMID: 16081794.
      View in: PubMed
    68. Yee C. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med. 2005 Apr 28; 3(1):17. PMID: 15860133.
      View in: PubMed
    69. Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A. 2005 May 03; 102(18):6461-6. PMID: 15824323.
      View in: PubMed
    70. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6. PMID: 15735047.
      View in: PubMed
    71. Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol. 2004 May 15; 172(10):5967-72. PMID: 15128778.
      View in: PubMed
    72. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004 May; 9(5):757-64. PMID: 15120337.
      View in: PubMed
    73. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May; 3(5):431-7. PMID: 12781360.
      View in: PubMed
    74. Yee C. Adoptive T cell therapy--immune monitoring and MHC multimers. Clin Immunol. 2003 Jan; 106(1):5-9. PMID: 12584044.
      View in: PubMed
    75. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002 Dec 10; 99(25):16168-73. PMID: 12427970.
      View in: PubMed
    76. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002 Nov; 110(10):1415-7. PMID: 12438439.
      View in: PubMed
    77. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002 Oct 17; 419(6908):734-8. PMID: 12384702.
      View in: PubMed
    78. Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer. 2002 Jun; 2(6):409-19. PMID: 12189383.
      View in: PubMed
    79. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol. 2001 Apr; 13(2):141-6. PMID: 11228405.
      View in: PubMed
    80. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000 Dec 04; 192(11):1637-44. PMID: 11104805.
      View in: PubMed
    81. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun; 5(6):677-85. PMID: 10371507.
      View in: PubMed
    82. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999 Feb 15; 162(4):2227-34. PMID: 9973498.
      View in: PubMed
    83. Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 1999 Feb 05; 283(5403):848-51. PMID: 9933169.
      View in: PubMed
    84. Greenberg PD, Finch RJ, Gavin MA, Kalos M, Lewinsohn DA, Lonergan M, Lord JD, Nelson BH, Ohlén C, Sing AP, Warren EH, Yee C, Riddell SR. Genetic modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J Sci Am. 1998 May; 4 Suppl 1:S100-5. PMID: 9619278.
      View in: PubMed
    85. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol. 1997 Oct; 9(5):702-8. PMID: 9368780.
      View in: PubMed
    86. Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 1996 Nov 01; 157(9):4079-86. PMID: 8892642.
      View in: PubMed
    87. Nagoya S, Greenberg PD, Yee C, Weisser KE, Sugawara H, Widmer MB, Slack J, Dower SK, Lupton SD, Overell RW. Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus. J Immunol. 1994 Aug 15; 153(4):1527-35. PMID: 8046231.
      View in: PubMed
    88. Greenberg PD, Nelson B, Gilbert M, Sing A, Yee C, Jensen M, Riddell SR. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Found Symp. 1994; 187:212-23; discussion 224-8. PMID: 7796672.
      View in: PubMed
    89. Yee C, Sutcliffe S, Messner HA, Minden MD. Interleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymphoma. 1992 May; 7(1-2):123-9. PMID: 1472922.
      View in: PubMed
    90. Chang H, Messner HA, Wang XH, Yee C, Addy L, Meharchand J, Minden MD. A human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest. 1992 Mar; 89(3):1014-20. PMID: 1311715.
      View in: PubMed
    91. Yee CS, Messner HA, Minden MD. Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol. 1991 Sep; 148(3):426-9. PMID: 1918171.
      View in: PubMed
    92. Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990 Mar 01; 65(5):1079-84. PMID: 2302659.
      View in: PubMed
    93. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989 Aug 01; 74(2):798-804. PMID: 2787680.
      View in: PubMed
    94. Yee C, Shiu RP. Degradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res. 1986 Apr; 46(4 Pt 1):1835-9. PMID: 3948167.
      View in: PubMed
    95. Yee C, Wong HY, Fewer HD, Rogers AG. Two cases of dysphagia due to cervical spine osteophytes successfully treated surgically. Can Med Assoc J. 1985 Apr 01; 132(7):810-2. PMID: 3978503.
      View in: PubMed
    96. Interleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice. Cellular Immunology.
    97. Genetic modification of T cell clones for therapy of human viral and malignant diseases. FASEB Journal. 11.
    98. Future perspectives in melanoma research. Journal of Translational Medicine. 14.
    99. Therapy of human viral and malignant diseases with gene-modified T cell clones. European Cytokine Network. 11:304-305.
    100. Monitoring antigen-specific responses in clinical trials of cancer immunotherapy. 425-453.
    101. Endogenous t-cell therapy. Cancer Journal (United States). 21:492-500.
    102. Adoptive therapy using antigen-specific T-cell clones.
    103. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. Journal for ImmunoTherapy of Cancer. 2.
    104. Recent advances in the use of antigen-specific T cells for the treatment of cancer. Update on Cancer Therapeutics. 1:333-342.
    105. Ethanol-dispersed polymer nanofibers as a highly selective cell isolation and release platform for CD4 + T lymphocytes. Advanced Functional Materials. 22:4448-4455.
    106. Adoptive T cell therapy. Journal of Translational Medicine. 3.
    107. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. Journal of Clinical Oncology. 34:3787-3795.
    108. Adoptive cellular therapy for the treatment of cancer. 343-361.
    109. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. Journal of Experimental Medicine. 213:1133-1139.
    110. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. Journal for ImmunoTherapy of Cancer. 1.
    111. Adoptive immunotherapy of melanoma. 439-465.
    YEE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description